Elsibucol

ATLANTA, Feb. 15 /PRNewswire-FirstCall/ -- AtheroGenics, Inc. , a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced that it expects to release its fourth quarter and fiscal 2005 year-end results of operations on Tuesday, February 28, 2006, before the U.S. financial markets open. (Logo: ) Company officials will provide a company update and discuss fourth quarter and 2005 year-end results via conference call and webcast on Tuesday, February 28, 2006, at 9:00 a.m. ET. The conference call may be accessed by dialing 1- 877-407-8031 (domestic) or 1-201-689-8031 (international), five minutes prior to the start time. A replay of the call will be available from 11:00 a.m. ET on February 28, until 11:59 p.m. ET on March 7, 2006. Rebroadcast numbers are 1-877-660-6853 (domestic) or 1-201-612-7415 (international), account number 286 and conference ID number 188890. To access the webcast, log on to the Company's Investor Relations Web site and click on the Webcast Access link. An archived version of this webcast will be available at the same location through April 21, 2006. About AtheroGenics AtheroGenics is focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, including heart disease (atherosclerosis), rheumatoid arthritis and asthma. The Company has two drug development programs currently in the clinic. AtheroGenics' lead compound, AGI-1067, is being evaluated in the pivotal Phase III ARISE clinical trial as an oral therapy for the treatment of atherosclerosis, in collaboration with AstraZeneca. AGI-1096 is a novel, oral agent in Phase I that is being developed for the prevention of organ transplant rejection in collaboration with Astellas. AtheroGenics also has preclinical programs in rheumatoid arthritis and asthma utilizing its proprietary vascular protectant(R) technology. For more information about AtheroGenics, please visit . Photo: AP Archive: PRN Photo Desk, photodesk@prnewswire.comAtheroGenics, Inc. CONTACT: Corporate Communications, Donna Glasky of AtheroGenics, Inc.,+1-678-336-2517, or investor@atherogenics.com; or Investor Relations,Lilian Stern of Stern Investor Relations, +1-212-362-1200, orlilian@sternir.com; or Media Relations, Katie Brazel of Fleishman Hillard,+1-404-739-0150, or brazelk@fleishman.com Web site: